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It’s now cheaper to print color figures in KI
Have you been concerned in the past about the cost of print-
ing color figures in Kidney International (KI)? KI has listened 
to your concerns and is now offering permanently reduced 
pricing for color figures—a flat fee of $500 per printed page, 
no matter how many color figures are on a page. This pricing 
is more affordable for authors and competitive with other top 
scientific journals. We want to make it easier for authors to 
publish the color figures that demonstrate important scien-
tific findings, and our new pricing reflects our commitment to 
achieving this goal.
Renalase and  
the cardiovascular 
complications  
of chronic  
kidney disease
Renalase is an oxidase that partic ipates 
in the disposal of catecholamines. 
Renalase is expressed in the kidney and 
in the heart and blood vessels, as well. 
As they report in this issue, Wu et al. 
generated a knockout of this enzyme 
and found that although the mice were 
viable, they had an increase in plasma 
catecholamine levels and hypertension. 
These mice had poor tolerance to coro­
nary ischemia and developed significant 
myocardial necrosis, an effect that was 
improved by infusion of recombinant 
renalase. Renalase also metabolizes 
nicotinamide adenine dinucleotide 
and hence may play a significant role in 
oxidative damage, frequently invoked in 
a variety of ischemic and other diseases 
of the cardiovascular system. Previous 
studies show renalase to be reduced in 
chronic kidney disease (CKD), suggest­
ing that perhaps this deficiency might 
explain the increased incidence of 
cardiovascular complications of CKD. 
See page 853.
Comparison of 
immunosuppressive 
therapies in 
transplantation
The use of calcineurin inhibitors has 
revolutionized immunosuppressive 
therapy in renal transplantation, but all 
new treatments come with side effects. 
Weir et al. conducted a randomized 
trial to compare two types of immuno­
suppression in renal allograft recipients; 
in one arm, patients received a combina­
tion of mycophenolate mofetil (MMF) 
and sirolimus, while those in the other 
arm received calcineurin inhibitors 
with MMF, tacrolimus, or cyclosporine. 
The patients had similar renal functions 
at entry and were followed for 2 years. 
After 1 year the measured glomerular 
filtration rate was slightly higher in the 
MMF/sirolimus group, a change that 
was no longer significant after 2 years. 
Remarkably, there were significantly 
more deaths in the calcineurin inhibi­
tor group. See page 897.
Transplant tourism 
and malignancies
Transplant tourism continues to occur 
despite the objections of most of us. 
Tsai et al. compared the outcomes of 
215 patients from Taiwan who went to 
mainland China for cadaveric trans­
plant tourism with the outcomes of 321 
patients who received cadaveric trans­
plants in Taiwan itself. Ten years after 
transplantation, the graft and patient 
survival rates were better in those who 
received transplants locally. Surpris­
ingly, the incidence of malignancy was 
almost three times higher among the 
transplant tourists. Needless to say, 
it is very difficult to draw statistical 
inferences here given the known and 
unknown disparities between the two 
groups. Whether this result was due to 
an inherent difference in the recipients 
or to the absence of ‘due diligence’ in 
vetting the donors clearly is unknown, 
but the finding remains sobering. 
See page 908.
